

# Biweekly Update 31-July 2020

#### **StrokeNet Enrollment Update**

ARCADIA	462/1100	CREST 2	1685/2480
Sleep SMART	268/3062	CREST H	145/500
TRANSPORT2	14/129	MOST	53/1200
I-ACQUIRE	22/240	ARCADIA-CSI	59/500
ASPIRE	1/700	SATURN	7/1456

## **StrokeNet Trial Updates**



Amendment V2 has been approved by the cIRB. The approved protocol and protocol signature page can be found in WebDCU in the toolbox. Complete the protocol signature page and upload into WebDCU.

The study team would like to welcome Mayo Jacksonville and Mass General to ARCADIA-CSI!

The following sites have been approved for Protocol Amendment V2 and are re-released to enroll:

UCSD La Jolla UCSD Hillcrest Hospital North Shore University Montefiore NYP Weill Cornell University of Iowa Hospital University of Penn

All sites must complete the Covid 19 Impact Assessment Form in WebDCU prior to re-opening. Sites still pending activation:

- Update all regulatory documents in WebDCU
- If you need to schedule your site readiness call do so by contacting study team members below

Sites who were open prior to the Covid-19 pause:

- · Update all regulatory documents
- Upload the approved continuing review documents

Please contact Tashia Harris, <a href="herridotl@ucmail.uc.edu">herridotl@ucmail.uc.edu</a> or Stephanie Kemp, <a href="mailto:skemp@standford.edu">skemp@standford.edu</a> with any questions.

#### From the CREST-2 Clinical Coordinating Center:

	CREST-2		CREST-2 StrokeNet
	CEA	885	387 (44% of total)
CDECT	CAS	800	136 (17% of total)
CREST-2	Total	1685	523 (31% of total)

To our StrokeNet sites: We need your help. There have been 4 randomizations for the month of July, with only one being from a StrokeNet site – the University of Florida at Shands.

Despite these challenging times, **39** StrokeNet sites have been approved to begin re-initiating enrollment for CREST-2. We have full faith that we can begin to ramp up enrollment once again but also **remain on target** to achieve our recruitment goals:

- 15 randomizations per month through October 2020
- 25 randomizations per month through May 2021
- 30 randomizations per month until December 2021

On July 21<sup>st</sup>, we circulated 3 recruitment flyers and a poster for the ultrasound lab to re-invigorate CREST-2 at your site. If you need more of these materials, please contact K. Guzman at <a href="mailto:guzman.kassondra@mayo.edu">guzman.kassondra@mayo.edu</a>.



- Enrollment into the ASPIRE study was paused on July 8 due to a potential issue with study drug stability. We are working to get you a timeline for resumption of enrollment soon.
  - During this pause, we ask that all sites where enrollment is suspended to continue to screen and consent patients for ASPIRE if possible. Randomizations must be held until after the suspension is lifted.
- All sites must complete a Remote and Electronic Informed Consent Implementation form to be submitted to the cIRB via the ASPIRE NCC Project Manager. This form is posted in WebDCU > ASPIRE Toolbox
- Please remember to update the COVID-19 Impact Assessment v2 in WebDCU to alert us to any changes in local restrictions on screening or enrollment.
- For sites still pending activation, please:
  - Upload/waive pending regulatory documents.
  - Enter addresses for study drug and lab kit shipments.
  - If CTA and cIRB approval in place, schedule readiness call.
- ASPIRE next Webinar is August 26, 2020 3:00p-4:00p EDT <a href="https://nihstrokenet.adobeconnect.com/trials/">https://nihstrokenet.adobeconnect.com/trials/</a>
   To take part in the conversation dial 1 (877) 621-0220 Passcode: 745694



**Re-Opening Update:** On Wednesday, June 16 the Central IRB (CIRB) at the U of Cincinnati approved our re-opening plan. On clinicaltrials.gov, we have removed the "trial suspension" designation and restored the open and "recruiting" designation.

4 of our 12 sites have completed all the steps to "re-open". Please reach out to Max Mays if you have any questions about getting your site re-opened.

Save the date: Our next PI/Co-I/Coordinator Webinar will be Thursday 13 August (12-1pm ET).



Our next PI and Coordinator call will be on **Monday**, 8/17/2020 at 11am ET. If anyone has topics they would like to discuss during the call, please send them to Kristina Balderson (<u>Kristina.balderson@duke.edu</u>) or Julia Gonzalez, (<u>Julia.jackson@duke.edu</u>).

As sites are planning to reopen to enrollment, please take inventory of your supplies and contact either Julia Gonzalez or Kristina Balderson for restock. When reaching out, please indicate the number of supplies needed, contact, and shipping location with confirmation that someone will be able to receive these shipments. Home addresses are approved for receiving shipments during this time of remote working or limited time at the site. For other questions or concerns, please contact Julia or Kristina.

Please make sure you have completed your BlueCloud recertification training by logging into the website: <a href="http://duke-transport2.trainingcampus.net">http://duke-transport2.trainingcampus.net</a>. Individuals who have expired or about to expire training have been sent reminder emails. **Note this is for the scoring of the Fugl Meyer, not the video training.** Annual renewal is now being tracked in WebDCU, which will notify coordinators directly when any of their staff have outdated training.

Congratulations to Medstar and Duke for their new enrollments this week. Congratulations to Baystate, Kentucky, and UAB for being re-open to enrollment amidst the COVID-19 restrictions. We are hopeful that by the end of August, the following sites will be reopened to enrollment: Emory, University of Cincinnati, and UPMC. Cleveland VA has a fully executed CTA and CIRB approval, and currently working through their local IRB submission. There are 14 subjects randomized in the trial. Six have completed the study and six have completed the intervention phase but are in the follow-up period.

Thank you for your continued effort and flexibility during this time!



Site Startup and Enrollment Updates: sites: 54; enrollments: 146/350

WE ARE BACK IN BUSINESS! Although many sites are still on restricted enrollment schedules due to COVID, we have enrolled 7 since reopening, bringing our total to 146, **41**% of our target. We are looking forward to reopening of the remaining 22 sites. We have **6** additional sites in the onboarding pipeline.

Due to **restrictions on research imaging** at some medical centers are still on hold at the moment, so **1-year CREST-H perfusion scans** may be delayed. We have gotten approval to delay the 1-year scans up to 3 months from reopening of imaging centers without incurring a protocol deviation.

In the setting of COVID, minimizing exposure of patients is critical. We currently recommend that CREST-H be discussed in the context of consenting for CREST-2, at the time other imaging is being mentioned. In order to save the patient an extra trip to your medical center, you can have the patient verbally agree to the perfusion scanning, and then have them sign the CREST-H consent when they arrive at the scanner. Please feel free to contact Jaya, Kevin, or one of the CREST-H PIs with any questions about this.

Contact emails: Randy Marshall <u>rsm2@columbia.edu</u>, Ron Lazar <u>rlazar@uabmc.edu</u>, Jaya Vijayan <u>vijayan.jaya@mayo.edu</u>, or Kevin Slane <u>KJS4@columbia.edu</u> with any questions.



#### Thank you for Enrolling in ARCADIA!

This summer has been challenging in many ways (COVID, working remotely and unusually high temperatures) and yet your teams have found ways to continue to enrolling and randomizing in ARCADIA – thank you!

Since our last summary, 32 sites have consented new subjects for a total of 1770 consented participants, an increase of 59 in a little more than a month – great way to re-start enrollment!

Twelve sites have randomized 15 subjects and now we have 462 randomized in ARCADIA. A special thanks to the teams at: Barnes (MO), Emory (GA), Greenville (SC), Harborview (WA), Hospital of the University of Pennsylvania (PA), Kaiser LA (CA), Mayo Jacksonville (FL), NYP Columbia (NY) and NYP Weill Cornell (NY), University of Mississippi (MS), University of Texas Health Science Center (TX) and UVA Medical Center (VA) for working thru these challenging times and getting the job done! Seven of those randomizations were pending pre-COVID and the other half were from new enrollments since June 22<sup>nd</sup> when new enrollment was re-started on a site by site basis. Excellent job everyone and thanks again for keeping ARCADIA moving forward!

We have re-opened 31 more sites and are now at 89 sites throughout the US that have been released to enroll along with 1 new site --welcome to the team at Methodist University Hospital in Tennessee!

We hope to continue to re-start sites as per the ARCADIA re-start plan and as possible at all the sites.

We understand many of your site cannot yet re-start, but those that can re-start enrollment, even if only remotely, please reach out to Rebeca (ra2356@cumc.columbia.edu) to review any pending items needed for your re-release.

For the sites still pending re-release, please take the time to read these instructions and complete the online forms once your site is allowing the re-start of enrollment in ARCADIA (if you haven't already done so):

- COVID-19 Impact Assessment with the General Comment PI attestation. The specified phrase confirms local
  institutional ability to re-open and that you will follow the ARACADIA re-start plan.
- Upload the cIRB site-wide approval letter dated 4/29/2020 (Protocol v5 16APR2020).
- Upload Protocol Signature Page (Protocol v5 16APR2020) this can be digitally signed by the PI.
- CIRB Approved Administrative Amendments the cIRB site-specific consent approval letter for your new consent forms – this upload is missing for many sites.
- CIRB Approved Informed Consent Form (v7) the PDF document; don't worry about translations for re-start, but please request them if you haven't already done so.
- Also, let Rebeca know if you need to submit to your local IRB before using the new consent forms.
- Email Rebeca (<u>ra2356@cumc.columbia.edu</u>) when your site has completed the requirements and is ready to be considered for re-release to enroll even if only doing remote screening, enrollments and follow ups.

In the meantime, please continue screening/keeping lists of potential participants that we can contact after the consent/randomization pause is lifted and stay in touch with patients to be sure they are weathering the crisis, and that their study-related medications continue.

As personnel changes and new staff come onboard often, we ask that you communicate with all of your team members regarding ARCADIA emails sent to the site's PI & PSC.

We thank you for your continued support and effort during these challenging times, but together we can move forward in ARACADIA.

In solidarity with all, we hope you will all keep safe!

**Webinar**: Our next PI and coordinator webinar will be August 25<sup>th</sup> at 2 PM Eastern--save the date! We're asking that at least 1 person from each site attend the monthly webinar and pass the information along to their team. Also, please send suggestions for topics you'd like discussed.

If you miss out on a webinar, you will soon be able to find the slides on the StrokeNet website <a href="https://www.nihstrokenet.org/intranet/minutes/trial-webinars">https://www.nihstrokenet.org/intranet/minutes/trial-webinars</a>



Thank you for your participation in Sleep SMART. We hope you are doing well, especially during this difficult time.

AMENDMENT: All sites should have received their amendment V5 site specific Informed Consent Documents (ICD). If you have not already, please upload your site CIRB approval Letter with the approved ICD to WebDCU.

RE-OPENING: On May 15, 2020, the CIRB approved our request to end the study-wide hold on in-person interactions, including enrollment, in Sleep SMART. Please report this to your local IRB, if appropriate. In WebDCU, please update the COVID Impact Assessment survey to reflect the current status of research at your institution and, if you are ready to re-start enrollments, to indicate confirmation (in 'general comments') of the statements in the memo dated May 15, 2020. Email Joelle to let her know when your local IRB has acknowledged the recent amendment. Pending NDMC queries may delay our ability to release you, so please catch up on these. You will not be released to enroll until you receive official permission through a WebDCU email. Since our re-opening, 41 sites have been re-released to enroll and have in-person interactions. If your site is not ready to enroll, but can complete in-person follow ups for the 3 and 6 month visits, please contact Joelle or Kayla with how to proceed.

#### Sites not previously released to enroll:

If your site was not previously released to enroll, please work toward site activation:

- CIRB submission
- Finalize the Clinical Trial Agreement and FusionHealth DUA and Consignment agreement
- Upload site and people documents to WebDCU
- Complete online trainings (<a href="https://webdcu.musc.edu/campus/">https://webdcu.musc.edu/campus/</a>)
- Complete readiness call (must have all contracts completed before this can be done)
- Please review the site to-do checklist found in the WebDCU toolbox

#### Sites that have already enrolled:

#### Don't forget these important reminders:

- Who is considered a proxy in Sleep SMART (for the outcome assessments)? Someone who spends
  enough time with subject in the opinion of the study team member and proxy to estimate how the subject
  would have answered the question. Proxies should leave blank any question to which they don't feel
  capable of providing an informed response.
- 2. Please perform the 3- and 6-month follow-up visits by telephone (unless you have permission by Kayla or Joelle for in-person follow ups or your site is open for new enrollments) within the assessment window(!), by a blinded study team member: 90 days (-14 days, +30 days), 180 days (-14 days, +60 days).
  - If a blinded study team member is not available, but the assessment can still be done within
    window by an unblinded study team member, please take advantage of that opportunity and
    report performance by the unblinded investigator.
- 3. If the window for the 3-month visit ends and you have not been able to reach a subject, please continue to reach out to him/her until the 6-month window begins. Please pursue 6-month assessments out to 3 months past the 6 month assessment time point before considering the subject lost to follow-up.
- 4. If you can't get in touch with the subject by phone to schedule the outcome assessment, please check the consent form to see if you have permission to contact him/her by text or email. Alternative contacts may also be found in the back of the consent. Sleep SMART also has a letter template available on our

- website (<a href="https://www.nihstrokenet.org/sleep-smart-trial/research-team">https://www.nihstrokenet.org/sleep-smart-trial/research-team</a> "unable to reach letter template") and for those on the verge of being lost to follow-up, a lost to follow-up letter.
- 5. Please check your response to Q05 of F123 (Hospital Discharge form). If "no" please double check as most responses should be "yes." Please keep in mind that the question addresses quality of inpatient stroke care so it queries use of antithrombotics during the first 2 days <u>after</u> hospital admission. Also, antithrombotics include both antiplatelets and anticoagulants.
- 6. As a reminder, please ask subjects to answer PROMIS questions as they are written (do not provide specific instructions to attempt to eliminate the influence of COVID).
- 7. Please check "Alerts" in WebDCU to find unresolved queries.
- 8. Visit our website: <a href="https://www.nihstrokenet.org/sleep-smart-trial/research-team">www.nihstrokenet.org/sleep-smart-trial/research-team</a> to review helpful materials.
- 9. If you missed one of our webinars, they are all available here: <a href="https://www.nihstrokenet.org/sleep-smart-trial/webinars">https://www.nihstrokenet.org/sleep-smart-trial/webinars</a>
- 10. Recall that the informed consent checklist is mandatory to use for all enrollments.
- 11. Please complete the alternative contact information section of the informed consent document, and provide this information in KOEO.
- 12. Before hospital discharge, help initiate contact between intervention subjects and the Care Team: Program Care Team number in subject's cell phone if they agree, help them make a first call while they are still hospitalized, and remind them they can receive \$10 for another call completed after discharge but within the first week out of the hospital.
- 13. Remember to charge the Nox T3 internal clock quarterly.
- 14. All responses to Data Clarification Requests (DCRs) must be submitted within 5 days of query generation, except those associated with Serious Adverse Events, which must be answered within 24 hours of query generation. Site payments are contingent upon the subject's data being entered, submitted, and all DCRs addressed.
- 15. For stroke outcome events, please be sure to upload documentation in the outcome packets that provides information about new stroke symptoms, including focal neurological symptoms and signs on exam, and associated dates.



SATURN has enrolled 7 patients!!!

SATURN Continuing Review documents are due 8/5/2020.

SATURN Remote Consent Implementation Forms must be completed by each site and returned to Kim Bernstein for cIRB submission.

Please continue to update the COVID Impact Assessment with information on anticipated timelines for resuming research activities. Please reach out to the study team when your site is able to resume research activities.

Sites that have not yet been released to enroll should complete the COVID Impact Assessment once they have been activated.

MGH has resumed shipping lab kits out to sites who have completed a readiness call. Please remember to confirm receipt of the lab kits in WebDCU once you are able to do so.

If you have any questions regarding SATURN and reopening enrollment at your site please contact: Kimberlee Bernstein NCC Project Manager <a href="mailto:gammk@ucmail.uc.edu">gammk@ucmail.uc.edu</a>
Sarah Marchina Prime Project Manager (BIDMC) <a href="mailto:smarchin@bidmc.harvard.edu">smarchin@bidmc.harvard.edu</a>



#### **MOST Enrollment Update:**

- Total randomizations: 53
- · Sites released to enroll with at least one patient consented: 21
- Congratulations to the following sites that have randomized in the past two weeks!
  - McLaren Flint, 2 subjects! Dr. Majihoo and Marci Roberts
  - M Health Fairview Southdale Hospital, 2 subjects! Dr. Bentho and Megan Tessmer
  - Wake Forest Baptist Medical Center, 1 subject! Dr. Bushnell and Karin Haski
  - o Memorial Hermann Texas Medical Center, 1 subject! Dr. Barreto and Jamey Franklin
  - o St. John Medical CenterSt. John Medical Center, 1 subject! Dr. Gordon and Lisa Shinder
- Congratulations to the following site that has been released to enroll!
  - Vanderbilt University Hospital
  - Henry Ford Hospital
- Congratulations to the following sites that have been reactivated for enrollment!
  - Abington Memorial Hospital
  - NYP Weill Cornell Medical Center
  - UCSD Health La Jolla
  - UCSD Medical Center Hillcrest Hospital
  - The Jewish Hospital
  - o Mercy Health West Hospital
  - Mercy Hospital Anderson
  - o Mercy Health Saint Mary's
  - UMASS Memorial Medical Center
  - North Shore University Hospital
- There are now 63 sites that have been released to enroll, 47 of which are actively recruiting!

#### MOST Update:

The StrokeNet Central IRB has approved the use of remote consent for MOST, including the centrally
managed eConsent through REDCap. We are excited to be the first StrokeNet Trial to test this consenting
method. Please return your Remote Consent Implementation form and reach out if you have any questions,
deedsss@uc.edu.

#### **MOST Appreciated:**

- For sites that are released to enroll please continue to complete screening logs in WebDCU™.
- For sites that have not been reactivated, please continue to update the COVID Impact Assessment in WebDCU™ with information on anticipated timelines for resuming research activities.

Thank you all for your efforts!

The PI Hotline is available 24/7 for any questions: 1-833-229-MOST

## **Coordinator Webinar**

Coordinator Webinars are a requirement for the NIH StrokeNet RCC Coordinators/Managers however, all are welcome to attend

Wednesday, 26-August, 1:30pm ET

Topic: FASTEST Trial Presentation

Presenter: Pooja Khanolkar, MPH – FASTEST Prime Project Manager, University of Cincinnati

(Introducing) Julie Denlinger, RN – FASTEST NCC Project Manager

Moderator: Dave Haney, Case Western Reserve University

To join the meeting: <a href="https://nihstrokenet.adobeconnect.com/coordinator/">https://nihstrokenet.adobeconnect.com/coordinator/</a>

To take part in the conversation you MUST dial in. 1 (877) 621-0220 Passcode: 434578

## **Steering Committee Call**

Steering Committee Calls are a requirement for all NIH StrokeNet RCCs; Please invite satellite sites to attend

The next Steering Committee call is scheduled for **Wednesday**, **12- August**, **2020**, **12 noon ET.** Agenda TBA. Minutes from the last Steering Committee call are attached.

**Note:** Wednesday, **14-October**, **2020**, is a regularly scheduled Steering Committee call. Please hold from **12 pm – 3pm ET** on your calendars as this will be our **fall network meeting**.

## **NINDS NEWS: \*NEW\* FOA Published**

As discussed on the 8-July Steering Committee webinar, the new StrokeNet FOA has been published. The next submission date is 14-October, 2020.

FOA and link: PAR-20-285 (https://grants.nih.gov/grants/guide/pa-files/PAR-20-285.html).

To listen to the 8-July discussion, please visit <a href="https://www.nihstrokenet.org/education/nih-strokenet-webinars-and-meetings">https://www.nihstrokenet.org/education/nih-strokenet-webinars-and-meetings</a>.

For questions, please contact Scott Janis (<a href="mailto:janisS@ninds.nih.gov">janisS@ninds.nih.gov</a>) or Claudia Moy (<a href="mailto:MoyC@ninds.nih.gov">MoyC@ninds.nih.gov</a>) with questions.

## **Grand Rounds**

Grand Rounds are a requirement for the NIH StrokeNet Trainees, however all are welcome to participate.

Thursday, August 27, 2020 4:00 pm ET

Topic: Infectious Causes of Stroke in Adults and Children- COVID-19, Influenza, and Others

Presenter: Shannon Agner, MD, PhD, Washington University

Mitch Elkind, MD, MS, Columbia University

Moderator: Randy Marshall, MD

To join the meeting: <a href="https://nihstrokenet.adobeconnect.com/grandrounds/">https://nihstrokenet.adobeconnect.com/grandrounds/</a>. Please enter as a guest, then your email address or your first and last name.

To take part in the conversation you MUST dial-in. (877) 621-0220 Passcode: 190825

## **Professional Development Webinar**

Professional Development Webinars are a requirement for the NIH StrokeNet Trainees

August 17, 2020

11:00 am ET

Presenter: Jordan Elm, PhD, Medical University of South Carolina

Presentation: Introduction to Biostatistics for Clinical Research

Moderator: TBA

To join the meeting: <a href="https://nihstrokenet.adobeconnect.com/pdw/">https://nihstrokenet.adobeconnect.com/pdw/</a>. Please enter as a guest, then your email address or your first and last name.

To take part in the conversation you MUST dial-in. (877) 621-0220 Passcode: 190825

## COVID-19: Information for NIH Applicants and Recipients of NIH Funding

Please visit <a href="https://grants.nih.gov/policy/natural-disasters/corona-virus.htm">https://grants.nih.gov/policy/natural-disasters/corona-virus.htm</a> to obtain additional information in regard to new resources and new information for NIH Applicants and Recipients of NIH Funding for COVID-19. Here is a summary of what's new since the last Nexus:

- Updated infographic describing the peer review process during COVID-19 highlights policies in effect for the upcoming round of due dates <a href="https://grants.nih.gov/policy/natural-disasters/corona-virus/review-process.htm">https://grants.nih.gov/policy/natural-disasters/corona-virus/review-process.htm</a>
- Guidance for Applicants Preparing Applications for the Fall 2020 Due Dates During the COVID-19 Pandemic https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-122.html
- Link to new dedicated page for funding opportunities specific to COVID-19 provides visibility into
  expiration dates and separates active vs expired FOAs
  <a href="https://grants.nih.gov/grants/guide/COVID-Related.cfm">https://grants.nih.gov/grants/guide/COVID-Related.cfm</a>
- New section on Funded Grants provides the ability to view COVID-19 related grant funding.
- All FAQs revised to align with NIH implementation of OMB memo M-20-26 https://grants.nih.gov/policy/natural-disasters/corona-virus/nih-omb-memo.htm
- Updated animal welfare FAQs <a href="https://grants.nih.gov/policy/natural-disasters/corona-virus/nih-omb-memo.htm">https://grants.nih.gov/policy/natural-disasters/corona-virus/nih-omb-memo.htm</a>

## **NIH StrokeNet Employment Opportunities**

For more information about StrokeNet employment opportunities, please visit http://nihstrokenet.org/education/employment-opportunities

Please share your satellites and study teams!

Contact: Jamey Frasure, PhD, RN, Administrative Director · frasurjs@ucmail.uc.edu https://www.nihstrokenet.org